
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
What are some effective strategies for compressing development timelines and derisking the process along the way? The PharmTech-Lonza Tech Talks Series on Integrated Services includes a 12-minute discussion of integrated drug substance form selection and optimization to drug product with Michael Grass, PhD, head of solid form services at Lonza.






